Inovio Pharma (INO) Shares Higher Amid New H7N9 Study in China
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Join SI Premium – FREE
Inovio Pharmaceuticals (AMEX: INO) shares are higher on the session amid a new report from the Center for Infectious Disease Research and Policy (CIDRP) at the University of Minnesota.
The study centers around H7N9 influenza in China and risks to infection. Three main drivers were: "direct contact with poultry or birds, environmental exposure, and chronic conditions except for hypertension."
Jiangsu province had 27 cases reported through May 27th, though two were excluded due to human-to-human transmission and missing data.
Inovio recent announced "that in a preclinical study of its influenza DNA vaccine against the newly emergent, virulent H7N9 flu virus it achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes. Interim results from a study in mice in a collaboration with researchers from the University of Pennsylvania and Canada's National Microbiology Laboratory in Winnipeg demonstrated that Inovio's H7N9 influenza DNA vaccine achieved greater than 1:40 hemagglutination inhibition (HAI) in 100% of tested animals (n=10), with a geometric mean HAI titer of 1:130 against the A/Anhui/1/13 strain of H7N9 virus. HAI titers at or above 1:40 are considered to denote protection against the influenza virus in humans. These mice received just two vaccinations three weeks apart and the samples tested were from week 5."
Shares of Inovio are up 21 percent Monday.
The study centers around H7N9 influenza in China and risks to infection. Three main drivers were: "direct contact with poultry or birds, environmental exposure, and chronic conditions except for hypertension."
Jiangsu province had 27 cases reported through May 27th, though two were excluded due to human-to-human transmission and missing data.
Inovio recent announced "that in a preclinical study of its influenza DNA vaccine against the newly emergent, virulent H7N9 flu virus it achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes. Interim results from a study in mice in a collaboration with researchers from the University of Pennsylvania and Canada's National Microbiology Laboratory in Winnipeg demonstrated that Inovio's H7N9 influenza DNA vaccine achieved greater than 1:40 hemagglutination inhibition (HAI) in 100% of tested animals (n=10), with a geometric mean HAI titer of 1:130 against the A/Anhui/1/13 strain of H7N9 virus. HAI titers at or above 1:40 are considered to denote protection against the influenza virus in humans. These mice received just two vaccinations three weeks apart and the samples tested were from week 5."
Shares of Inovio are up 21 percent Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Neutral Rating on Inovio Pharmaceuticals (INO)
- INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- INOVIO to Report Second Quarter Financial Results on August 12, 2026
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
